Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1581-1600 of 3,900 trials

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Guselkumab for Kids with Inflammatory Conditions

We are studying the long-term safety of guselkumab in children with ulcerative colitis, Crohn’s disease, or juvenile psoriatic arthritis. This research aims to ensure the medication is safe for young patients.

Crohn's DiseaseJuvenile Psoriatic ArthritisUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementDermatologyGastroenterologyRheumatology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

RAS G12C-Mutated Non-Small Cell Lung Cancer: RMC-6291 Study

We are studying a new treatment combining RMC-6291 with pembrolizumab and other therapies for patients with RAS G12C-mutated lung cancer. The goal is to evaluate safety and early signs of effectiveness.

Non-small Cell Lung CancerSafety phase (I)No PlaceboInvestigational MedicinesOncologyPulmonology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Tick-Borne Encephalitis: Novel Cytokine Release Assay

We are studying a new test to measure immune responses to Tick-Borne Encephalitis in healthy and immunosuppressed individuals. This research aims to improve understanding of how well the immune system responds to the virus and vaccination.

Tick-borne Encephalitis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyInfectious Diseases

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

HIV and Hepatitis B: Bepirovirsen Treatment Study

We are studying a new treatment for people living with both HIV and chronic Hepatitis B. The trial aims to see if bepirovirsen can help reduce the Hepatitis B virus in patients already receiving antiretroviral therapy.

Hepatitis B1-2 yearsEfficacy phase (II)Investigational MedicinesInfectious DiseasesInternal Medicine

Ovarian and Breast Cancer: zAvatar Test Study

We are exploring whether the zAvatar test can help guide treatment decisions for patients with relapsed ovarian cancer and metastatic breast cancer. This study compares outcomes from the zAvatar test approach to standard care.

Breast CancerOvarian CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Ulcerative Colitis: Oral Mesalazine Treatment

We are studying an oral medication for people with mild to moderate ulcerative colitis to see if it helps induce remission of symptoms. The trial will assess various measures of improvement after treatment.

Ulcerative Colitis3-6 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Bipolar Disorder Type II: Lithium vs. Lamotrigine Study

We are comparing the effects of lithium and lamotrigine on mood stabilization in people with bipolar disorder type II. The goal is to see which treatment may better reduce symptoms and improve daily functioning.

Bipolar Disorder, Type II1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Hamstring Injury: Hyperbaric Oxygen Therapy Study

We are investigating whether hyperbaric oxygen therapy helps athletes and military personnel recover faster from hamstring injuries. The study will also look at safety and changes in injury over time.

Hamstring InjuryConfirmation phase (III)No PlaceboStandard MedicinesOrthopedics and Traumatology

Alzheimer's Disease: Efavirenz Study

We are investigating whether Efavirenz can affect certain biomarkers in people with early Alzheimer's Disease. This study aims to understand its safety and how it works in the body.

Alzheimer's Disease3-6 monthsSafety phase (I)Efficacy phase (II)Standard MedicinesNeurology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan Study

We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.

Esophageal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology